Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$6.1B

Dec1Thu

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation is a biotechnology company focused on developing innovative cell therapies for cancer treatment. Operating in the health care sector, it aims to address significant unmet medical needs with its advanced therapies.

Key Metrics to Watch

Clinical Trial Progress

Updates on clinical trials are crucial as they can indicate the potential for future revenue and product launches.

Progress in ongoing trials

Partnership Developments

New partnerships can enhance research capabilities and funding, impacting future growth.

New collaborations or agreements

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In the last quarter, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, indicating a positive surprise. However, the stock saw a slight decline the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to exploring new partnerships.
Plans to provide updates on regulatory submissions.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, expecting updates on clinical trials and potential partnerships. The stock has shown a tendency to react positively to earnings surprises.

Bull Case

If Legend Biotech announces significant progress in clinical trials or new partnerships, it could lead to a strong upward movement in the stock price.

Bear Case

Conversely, any delays in clinical trials or lack of new partnerships could result in a negative reaction from investors.

Key Metrics to Watch

Clinical Trial Progress

Progress in ongoing trials

Updates on clinical trials are crucial as they can indicate the potential for future revenue and product launches.

Partnership Developments

New collaborations or agreements

New partnerships can enhance research capabilities and funding, impacting future growth.

Regulatory Approvals

Updates on FDA submissions or approvals

Regulatory milestones are key for commercialization and can significantly affect stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of ongoing clinical trials?

The success or delays in these trials will heavily influence investor sentiment and future revenue potential.

Are there any new partnerships or collaborations in the pipeline?

New partnerships can provide additional funding and resources, which are critical for the company's growth strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for new partnerships that could significantly enhance Legend Biotech's growth prospects this quarter.

Supporting Evidence

The company has a history of surprising the market with positive updates on clinical trials.

Recent trends in the biotech sector indicate increased collaboration opportunities.

Options pricing suggests lower expected volatility than historical averages, indicating potential for a surprise.

Key Risk

If the company announces a major partnership or significant trial progress, it could shift market expectations dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching for developments that could impact the company's growth trajectory.

Bull Confirmed If

Positive updates on clinical trial progress or new partnerships would confirm the bull case.

Bear Confirmed If

Any significant delays in clinical trials or lack of new partnerships would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% move, suggesting that investors expect some volatility around the earnings announcement.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests the stock could rise by around 1.71%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of about 6.91%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the status of ongoing clinical trials and any upcoming milestones.
2Information regarding potential new partnerships or collaborations.
3Updates on regulatory submissions and expected timelines.
4Management's outlook on market conditions and competitive landscape.
5Any commentary on financial projections or funding needs.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

Clinical Trial Progress

Updates on clinical trials are crucial as they can indicate the potential for future revenue and product launches.

Progress in ongoing trials

Partnership Developments

New partnerships can enhance research capabilities and funding, impacting future growth.

New collaborations or agreements

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In the last quarter, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, indicating a positive surprise. However, the stock saw a slight decline the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to exploring new partnerships.
Plans to provide updates on regulatory submissions.

Expectations

Wall Street Expectations

Bull Case

If Legend Biotech announces significant progress in clinical trials or new partnerships, it could lead to a strong upward movement in the stock price.

Bear Case

Conversely, any delays in clinical trials or lack of new partnerships could result in a negative reaction from investors.

Key Metrics to Watch

Clinical Trial Progress

Progress in ongoing trials

Updates on clinical trials are crucial as they can indicate the potential for future revenue and product launches.

Partnership Developments

New collaborations or agreements

New partnerships can enhance research capabilities and funding, impacting future growth.

Regulatory Approvals

Updates on FDA submissions or approvals

Regulatory milestones are key for commercialization and can significantly affect stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of ongoing clinical trials?

The success or delays in these trials will heavily influence investor sentiment and future revenue potential.

Are there any new partnerships or collaborations in the pipeline?

New partnerships can provide additional funding and resources, which are critical for the company's growth strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for new partnerships that could significantly enhance Legend Biotech's growth prospects this quarter.

Supporting Evidence

The company has a history of surprising the market with positive updates on clinical trials.

Recent trends in the biotech sector indicate increased collaboration opportunities.

Options pricing suggests lower expected volatility than historical averages, indicating potential for a surprise.

Key Risk

If the company announces a major partnership or significant trial progress, it could shift market expectations dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching for developments that could impact the company's growth trajectory.

Bull Confirmed If

Positive updates on clinical trial progress or new partnerships would confirm the bull case.

Bear Confirmed If

Any significant delays in clinical trials or lack of new partnerships would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% move, suggesting that investors expect some volatility around the earnings announcement.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests the stock could rise by around 1.71%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess.

Miss

A miss could lead to a decline in stock price, with history suggesting an average drop of about 6.91%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the status of ongoing clinical trials and any upcoming milestones.
2Information regarding potential new partnerships or collaborations.
3Updates on regulatory submissions and expected timelines.
4Management's outlook on market conditions and competitive landscape.
5Any commentary on financial projections or funding needs.